Masanobu Oshima Selected Research

Adenocarcinoma

10/2009	Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models.
4/2009	Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
1/2009	Matrix metalloproteinase 7 is required for tumor formation, but dispensable for invasion and fibrosis in SMAD4-deficient intestinal adenocarcinomas.
1/2002	Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masanobu Oshima Research Topics

Disease

77	Neoplasms (Cancer) 04/2024 - 01/2002
43	Carcinogenesis 04/2024 - 01/2002
28	Stomach Neoplasms (Stomach Cancer) 02/2020 - 10/2005
17	Inflammation (Inflammations) 01/2023 - 10/2005
9	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 04/2007
9	Colonic Neoplasms (Colon Cancer) 01/2022 - 12/2003
9	Gastritis 01/2019 - 10/2009
8	Metaplasia 01/2019 - 04/2004
7	Adenoma (Adenomas) 04/2024 - 01/2002
7	Hyperplasia 01/2019 - 04/2004
6	Carcinoma (Carcinomatosis) 12/2020 - 10/2006
6	Infections 01/2019 - 04/2002
5	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2011 - 01/2002
5	Polyps 10/2005 - 01/2002
4	Neoplasm Metastasis (Metastasis) 11/2023 - 06/2004
4	Adenocarcinoma 10/2009 - 01/2002
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2021 - 03/2011
3	Colitis 01/2019 - 02/2008
3	Hamartoma 09/2010 - 04/2009
3	Hepatocellular Carcinoma (Hepatoma) 11/2009 - 04/2002
3	Helicobacter Infections 06/2008 - 04/2004
3	Intestinal Polyps 10/2005 - 01/2002
2	Melanoma (Melanoma, Malignant) 01/2022 - 06/2004
2	Glioblastoma (Glioblastoma Multiforme) 12/2020 - 01/2019
2	Brain Neoplasms (Brain Tumor) 01/2019 - 10/2009
2	Bacterial Infections (Bacterial Infection) 02/2012 - 02/2011
2	Intestinal Polyposis (Polyposis, Intestinal) 08/2003 - 04/2002
1	Ureteral Neoplasms (Ureteral Cancer) 01/2024
1	Dermatitis 01/2023

Drug/Important Bio-Agent (IBA)

18	Dinoprostone (PGE2)FDA Link 01/2019 - 04/2004
14	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2018 - 01/2002
13	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2002
12	ProstaglandinsIBA 11/2017 - 01/2002
11	CytokinesIBA 10/2023 - 10/2005
10	Prostaglandins EIBA 03/2013 - 08/2003
10	beta CateninIBA 11/2009 - 04/2002
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2011 - 10/2005
5	Transforming Growth Factor-beta Type II ReceptorIBA 04/2023 - 02/2015
5	LigandsIBA 12/2022 - 06/2004
5	Interleukin-11 (Interleukin 11)IBA 01/2021 - 03/2009
5	EnzymesIBA 12/2020 - 04/2004
5	spasmolytic polypeptideIBA 01/2019 - 10/2005
5	Messenger RNA (mRNA)IBA 01/2019 - 12/2017
5	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018 - 02/2012
5	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2013 - 01/2002
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2017
4	CarcinogensIBA 10/2021 - 01/2002
4	Prostaglandin-E SynthasesIBA 10/2015 - 04/2004
3	CateninsIBA 01/2022 - 10/2015
3	InterleukinsIBA 01/2021 - 03/2009
3	Interleukin-6 (Interleukin 6)IBA 01/2021 - 03/2009
3	AcidsIBA 02/2020 - 11/2016
3	MicroRNAs (MicroRNA)IBA 01/2019 - 03/2013
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 03/2011
3	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2019 - 10/2015
3	Toll-Like Receptor 2IBA 01/2019 - 11/2012
3	ChemokinesIBA 01/2018 - 06/2004
3	Conditioned Culture MediaIBA 12/2017 - 06/2008
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2012 - 01/2002
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 02/2012 - 01/2002
3	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 09/2010 - 04/2009
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2008 - 01/2002
2	AntioxidantsIBA 04/2024 - 06/2015
2	Activins (Activin)IBA 10/2023 - 01/2019
2	InflammasomesIBA 01/2022 - 01/2018
2	CurcuminIBA 12/2020 - 10/2015
2	RNA (Ribonucleic Acid)IBA 12/2020 - 01/2018
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2018 - 10/2005
2	Estrogens (Estrogen)FDA Link 01/2018 - 01/2018
2	EpiregulinIBA 12/2017 - 04/2011
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 01/2017 - 12/2008
2	Biomarkers (Surrogate Marker)IBA 03/2016 - 02/2015
2	AntibodiesIBA 01/2015 - 06/2004
2	Bromodeoxyuridine (BrdU)IBA 01/2012 - 03/2010
2	Dextran SulfateIBA 03/2011 - 02/2008
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2009 - 04/2007
2	Antisense RNA (Anti-Sense RNA)IBA 06/2004 - 12/2003
1	MidkineIBA 04/2024
1	CatalaseIBA 04/2024
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 04/2024
1	UromodulinIBA 01/2024
1	Immune Checkpoint InhibitorsIBA 11/2023
1	Interferon Type IIBA 11/2023
1	activin AIBA 10/2023
1	Calcibiotic Root Canal SealerIBA 10/2023
1	CollagenIBA 04/2023
1	matrigelIBA 04/2023
1	bisphenol F diglycidyl etherIBA 01/2023
1	OsteopontinIBA 01/2023
1	Peptides (Polypeptides)IBA 01/2023
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023

Therapy/Procedure

9	Therapeutics 04/2024 - 10/2013
3	Chemoprevention 01/2019 - 02/2008
2	Glycemic Control 01/2024 - 01/2024
2	Immunotherapy 11/2023 - 01/2021
2	Transplantation 01/2022 - 01/2018
2	Lasers (Laser) 01/2019 - 01/2018
2	Drug Therapy (Chemotherapy) 01/2018 - 10/2015
1	Investigational Therapies (Experimental Therapy) 04/2024
1	Nephroureterectomy 01/2024